Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Sunitinib (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CROSS-J-RCC
- 20 Mar 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 2017 Genitourinary Cancers Symposium.
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 01 Feb 2014 Primary endpoint 'Progression-free-survival-duration' has not been met.